Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Thursday, Health Canada, said it had officially approved the use of the new vaccine brand names.

Nathan Denette/The Canadian Press

The pandemic has created a whole new vocabulary, one that is ever-changing, and not always easy to follow.

Way back in December, 2019, we started out with a novel coronavirus. Not long after it got the unwieldy moniker severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short.

Then, for the sake of convenience, we just started calling the virus and the disease it causes by the same name: COVID-19. Which, by the way, is an abbreviation for coronavirus disease of 2019.

Story continues below advertisement

As our virus knowledge became more sophisticated, so did our language. It also became a mouthful. The B.1.1.7, B.1.351 and B.1.617 variants, became, mercifully, Alpha, Beta and Delta respectively.

(And, if you’re wondering, these changes come about through consensus of scientists, generally led by the World Health Organization.)

When vaccines were created, we distinguished them by their manufacturers’ names: the Pfizer vaccine, the Moderna vaccine, and so on.

But now the vaccines have brand names. Brace yourself because these are some tongue-twisters: Comirnaty is the new name for the Pfizer-BioNTech vaccine; SpikeVax is the name chosen by Moderna; Vaxzevria is the product name AstraZeneca has adopted.

Chief medical officers of health can’t be all things to all people

Will the COVID-19 pandemic become endemic?

Thursday, in a pretty standard bureaucratic announcement, Health Canada said it had officially approved the use of these names.

For some puzzling reason, this sent a lot of people into a tizzy, especially on social media. Mind you, cyberspace is a place where dramatic overreactions are standard fare.

The attacks on Health Canada began almost immediately, as if the entire COVID-19 response was being abandoned become some low-level lackey produced a couple of tweets.

Story continues below advertisement

The only thing that the public needs to retain from this announcement is that it’s largely irrelevant.

The vaccines are exactly the same. The only thing that will change is the packaging – and the public generally doesn’t even see that.

The timing is not exactly conspiratorial either.

The European Medicines Agency approved the use of brand names in the spring. The U.S. Food and Drug Administration recently gave formal approval to the Pfizer COVID-19 vaccine – it had previously been granted only emergency use authorization – and then use of brand names was permitted.

On Thursday, Health Canada also flipped its interim approval into full approval and, again, that allowed companies to use brand names.

There is absolutely no reason for Health Canada to not rubber stamp this change, and even less reason for people to get worked up about it.

Story continues below advertisement

Companies have the right to name their products and, especially when competing products are largely indistinguishable, branding is important. It’s also standard practice.

We don’t call Viagra the Pfizer erectile dysfunction drug, and we don’t call Cialis the Eli Lilly ED drug. The names matter, especially when drugs are advertised, as they are heavily in the United States. Nor do we pay too much attention to the fact that drugs also have generic names, sildenafil for Viagra and tadalafil for Cialis.

COVID-19 vaccines are here to stay for a long while yet. Companies are competing fiercely to distinguish themselves from the competition, with consumers and governments.

Much of the social-media chatter revolves around the belief that some of the brand names of these vaccine are a tad ridiculous.

Comirnaty – pronounced koh-MIHR-nuh-tee – is the most easily and fiercely ridiculed.

According the pharmaceutical industry newsletter Fierce Pharma, the name uses the prefix “co-” to represent community; “mirna” stands for mRNA; and the “-ty” as a nod toward the end of both “community” and “immunity.”

Story continues below advertisement

Clearly someone was overthinking this, and when that happens you end up with a brand name that sounds like one of Elon Musk’s children.

Not that the other manufacturers have done much better.

SpikeVax sounds like a weed killer or, if we’re being generous, a cartoon superhero. But at least Moderna’s references are simply self-evident: This is a vaccine that targets the spike protein.

Vaxzevria, unfortunately, sounds like a painful sexually transmitted disease.

But, again, it doesn’t matter a whit.

What matters is that people get vaccinated. Whether the shot is called “Pfizer vaccine” or “Comirnaty,” it will ensure that you have a lesser chance of being infected with, getting or dying of COVID-19.

Story continues below advertisement

The name on the box is immaterial.

Health Canada authorized brand-name changes for the approved COVID-19 vaccines in Canada. Pfizer-BioNTech is now Comirnaty, Modern is SpikeVax and AstraZeneca is Vaxzevria. The internet reacted.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies